HISAMITSU PHARMACEUTICAL CO.,INC. (4530) Stock Price

Hisamitsu Pharmaceutical is a company primarily engaged in the pharmaceutical business. The company forms a corporate group that includes 19 consolidated subsidiaries, 3 affiliated companies accounted for using the equity method, and 1 non-consolidated subsidiary. The pharmaceutical business manufactures and sells products both domestically and internationally, with a particular focus on over-the-counter (OTC) medications such as allergy treatment drugs.

Domestically, Hisamitsu Pharmaceutical handles direct manufacturing and sales, while Hisamitsu Wellness Co., Ltd. manages mail-order sales. Hisamitsu-Sanofi Co., Ltd. supplies allergy treatment drugs, and Yutoku Pharmaceutical Industries Co., Ltd. handles manufacturing and sales. These companies supply products to Hisamitsu Pharmaceutical.

Internationally, Hisamitsu US Incorporated serves as a holding company, with Hisamitsu America Incorporated handling sales in the United States. Noven Pharmaceuticals manufactures and sells prescription pharmaceuticals, while Hisamitsu Pharmatica do Brasil Ltda. manages manufacturing and sales in Brazil.

Additionally, Hisamitsu UK Limited and Hisamitsu Italia S.r.l. conduct development activities focused primarily on regulatory applications in Europe. In the Asia region, Hisamitsu Vietnam Pharmaceutical Company Limited handles manufacturing and sales in Vietnam, and Hisamitsu Pharmaceutical Technology Consulting (Beijing) Co., Ltd. manages marketing operations in China.

Beyond pharmaceuticals, Hisamitsu Pharmaceutical operates urban cable television broadcasting and internet connection services. CRCC Media Co., Ltd. and Saga City Vision Co., Ltd. provide these services. Additionally, Taiyo Co., Ltd. operates a general insurance agency business, and SAGA Hisamitsu Springs Co., Ltd. manages a volleyball team.

In advertising-related operations, Hisamitsu Agency Co., Ltd. handles advertising brokerage, and Maruton Sangyo Co., Ltd. manufactures and sells packaging materials. Through these diverse business activities, Hisamitsu Pharmaceutical pursues market expansion both domestically and internationally.

Hisamitsu Pharmaceutical is pursuing advances in transdermal drug delivery system (TDDS) technology and patch formulation development. The company's management philosophy is to improve quality of life (QOL) for people worldwide and contribute to building a healthier society. Its corporate mission is to spread the culture of "care and treatment" globally and promote compassionate therapeutic practices.

The company has established "HX2025 (Hisamitsu Transformation 2025)," a medium-term management plan targeting consolidated revenue compound annual growth rate (CAGR) of 5% or more, return on equity (ROE) of 8% or more, and overseas sales ratio of 50% or more by fiscal year 2025. The company positions this as a five-year transformation period focused on recovering from COVID-19 impacts and improving profitability.

Domestically, in the prescription pharmaceutical business, the company is strengthening information provision to healthcare professionals and advancing new drug formulation development. In the over-the-counter pharmaceutical business, it aims to expand existing product sales and develop new products. Internationally, the company leverages intellectual property and manufacturing technology to establish brands and expand market share.

Particularly, centered on the Salonpas® brand, the company targets growth in seven countries and regions where it has local subsidiaries, while pursuing market share expansion in other regions. To strengthen research and development capabilities, the company has consolidated research functions into the "SAGA Global Research Center" to accelerate development speed and strengthen coordination with production divisions.

Hisamitsu Pharmaceutical is advancing ESG (environment, social, and governance) and SDGs (Sustainable Development Goals) initiatives, aiming to contribute to building a sustainable society. The company identifies material issues necessary for addressing social challenges and achieving sustainable growth, fulfilling its corporate social responsibility.